Komori
Results4975JCU CORPORATIONMaterials and Chemicals

Summary of Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending March 2027 (Japanese GAAP) (Consolidated)

Revenue increased 11.3% year on year, driven by stronger demand from the electronics sector and higher shipments, while operating profit also rose 1.5%. Meanwhile, interim net income attributable to owners of the parent was down 0.1%, essentially flat, due in part to lower revenue and profit in the Equipment business.

Worth reading
47Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
11.3
Year-on-year change in revenue (%)
Wording
Conditional
How definitive the wording is.

Results for this period

Interim period (second quarter)1 April 2026–30 September 2026ConsolidatedJapanese GAAP
Net Sales15,875¥ millionYear on year +11.3%Progress 47.5%
Operating profit5,866¥ millionYear on year +1.5%Progress 47.7%
Ordinary income6,101¥ millionYear on year +5.6%Progress 48.8%
Net income attributable to owners of the parent4,355¥ millionYear on year -0.1%Progress 49.5%

The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.

Net income per share¥176.89
Financial position at period-end
Total assets64,639¥ million
of which net assets 59,507 ¥ millionEquity ratio 92.1%vs. prior year-end +5.0pt

塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.

Cash inflows and outflows
Operating+5,722
Investment-2,089
Financials-1,667
Net change+1,966

Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.

Cash and cash equivalents at end of period¥24,290 million
Segment revenuePharmaceuticals business ¥14,613 million (YoY +16.9%), Equipment business ¥1,262 million (YoY -28.2%)
Segment profitPharmaceuticals business ¥6,226 million (YoY +4.3%), Equipment business ¥157 million (YoY -46.5%)
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥33,400 million (YoY +12.6%)
Operating profit¥12,300 million (YoY +1.2%)
Ordinary income¥12,500 million (YoY +0.4%)
Net income¥8,800 million (YoY -3.0%)
Annual Dividend Forecast¥95 → ¥180
Factors Behind Changes in Business Performance

Demand for high-performance electronic devices for the electronics sector remained strong, and shipments of various products increased. The Chemicals business posted higher revenue and profit, while revenue and segment profit declined in the Equipment business, although orders received and the order backlog increased on stronger demand for capital investment.

Disclosure regarding the going concern assumption

None

Change in accounting policy
基準改正に伴う変更 Noneそれ以外の変更 None見積りの変更 None修正再表示 None
Changes in the scope of consolidationNew 0 / Excluded 0 / Company name None
Impairment lossNone
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of property, plant and equipment ¥2 million / Extraordinary loss Loss on disposal of property, plant and equipment ¥2 million
Depreciation and amortization¥1,219 million
Orders received and order backlogOrders received ¥1,547 million / Order backlog ¥714 million
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingAvailable (for institutional investors and analysts)
Issued Shares at Period-End26,219,049 shares
Treasury Shares at Period-End1,593,684 shares
Results for this period
ItemDetails
Fiscal Period ClassificationInterim period (second quarter)
Accounting standardsJapanese GAAP
Consolidated / non-consolidatedConsolidated
Period Covered1 April 2026–30 September 2026
Net Sales¥15,875 million (YoY +11.3%)
Operating profit¥5,866 million (YoY +1.5%)
Ordinary income¥6,101 million (YoY +5.6%)
Profit attributable to owners of the parent¥4,355 million (YoY -0.1%)
Net income per share¥176.89
Equity ratioEnd of the current fiscal period 92.1 / End of previous period 87.1
Total assets¥64,639 million
Net assets¥59,507 million
Cash flows from operating activities¥5,722 million
Cash flows from investing activities¥-2,089 million
Cash flows from financing activities¥-1,667 million
Cash and cash equivalents at end of period¥24,290 million
Full-year earnings forecastNet Sales ¥33,400 million (YoY +12.6%) / Operating profit ¥12,300 million (YoY +1.2%) / Ordinary income ¥12,500 million (YoY +0.4%) / Net income ¥8,800 million (YoY -3.0%)
Annual Dividend Forecast¥95 → ¥180
Segment revenuePharmaceuticals business ¥14,613 million (YoY +16.9%), Equipment business ¥1,262 million (YoY -28.2%)
Segment profitPharmaceuticals business ¥6,226 million (YoY +4.3%), Equipment business ¥157 million (YoY -46.5%)
Orders received and order backlogOrders received ¥1,547 million / Order backlog ¥714 million
Depreciation and amortization¥1,219 million
Impairment lossNone
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of property, plant and equipment ¥2 million / Extraordinary loss Loss on disposal of property, plant and equipment ¥2 million
Disclosure regarding the going concern assumptionNone
Change in accounting policyChanges due to revisions to standards None / Other changes None / Change in accounting estimate None / Restatement None
Changes in the scope of consolidationNew 0 / Excluded 0 / Company name None
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingAvailable (for institutional investors and analysts)
Issued Shares at Period-End26,219,049 shares
Treasury Shares at Period-End1,593,684 shares
Factors Behind Changes in Business PerformanceDemand for high-performance electronic devices for the electronics sector remained strong, and shipments of various products increased. The Chemicals business posted higher revenue and profit, while revenue and segment profit declined in the Equipment business, although orders received and the order backlog increased on stronger demand for capital investment.
Items this document does not state (6)
Operating MarginRevision to Earnings ForecastPayout ratioShareholder Return PolicyRegional salesMaterial subsequent events

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Demand for high-performance electronic devices, including generative AI and server-related products, was strong, and shipments of various products increased. In the Equipment business, orders received and the order backlog increased on demand for capital investment, but revenue and segment profit declined.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.